123 related articles for article (PubMed ID: 9270500)
1. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions.
Rudolph P; Schubert C; Schubert B; Parwaresch R
J Am Acad Dermatol; 1997 Aug; 37(2 Pt 1):169-78. PubMed ID: 9270500
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
3. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study.
Rieger E; Hofmann-Wellenhof R; Soyer HP; Kofler R; Cerroni L; Smolle J; Kerl H
J Cutan Pathol; 1993 Jun; 20(3):229-36. PubMed ID: 8103531
[TBL] [Abstract][Full Text] [Related]
4. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions.
Lebe B; Pabuççuoğlu U; Ozer E
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):160-4. PubMed ID: 17525627
[TBL] [Abstract][Full Text] [Related]
5. Proliferation antigens in cutaneous melanocytic tumors--an immunohistochemical study comparing the transferrin receptor and the Ki 67 antigen.
Soyer HP; Smolle J; Smolle-Juettner FM; Kerl H
Dermatologica; 1989; 179(1):3-9. PubMed ID: 2569990
[TBL] [Abstract][Full Text] [Related]
6. Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases.
Phadke PA; Rakheja D; Le LP; Selim MA; Kapur P; Davis A; Mihm MC; Hoang MP
Am J Surg Pathol; 2011 May; 35(5):656-69. PubMed ID: 21436676
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
[TBL] [Abstract][Full Text] [Related]
8. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions.
Li LX; Crotty KA; McCarthy SW; Palmer AA; Kril JJ
Am J Dermatopathol; 2000 Dec; 22(6):489-95. PubMed ID: 11190439
[TBL] [Abstract][Full Text] [Related]
9. WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi.
Rosner K; Mehregan DR; Moussai D; Abrams J; Tromp G; Mehregan DA
J Cutan Pathol; 2009 Oct; 36(10):1077-82. PubMed ID: 19615003
[TBL] [Abstract][Full Text] [Related]
10. Role of In Vivo Reflectance Confocal Microscopy in the Analysis of Melanocytic Lesions.
Serban ED; Farnetani F; Pellacani G; Constantin MM
Acta Dermatovenerol Croat; 2018 Apr; 26(1):64-67. PubMed ID: 29782304
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
12. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
Skender-Kalnenas TM; English DR; Heenan PJ
J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
[TBL] [Abstract][Full Text] [Related]
13. Pigmented Spitz nevi: improvement of the diagnostic accuracy by epiluminescence microscopy.
Steiner A; Pehamberger H; Binder M; Wolff K
J Am Acad Dermatol; 1992 Nov; 27(5 Pt 1):697-701. PubMed ID: 1430390
[TBL] [Abstract][Full Text] [Related]
14. Melanocytic nevi clinically simulating melanoma.
Makino E; Uchida T; Matsushita Y; Inaoki M; Fujimoto W
J Dermatol; 2007 Jan; 34(1):52-5. PubMed ID: 17204102
[TBL] [Abstract][Full Text] [Related]
15. Molecular diagnosis of a benign proliferative nodule developing in a congenital melanocytic nevus in a 3-month-old infant.
Murphy MJ; Jen M; Chang MW; Grant-Kels JM; Makkar H
J Am Acad Dermatol; 2008 Sep; 59(3):518-23. PubMed ID: 18640742
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 immunostaining and stereologic estimation of nuclear volume in melanocytic skin tumors.
Ozer E; Sağol O; Kuyucuoğlu F
Anal Quant Cytol Histol; 1999 Feb; 21(1):42-6. PubMed ID: 10068774
[TBL] [Abstract][Full Text] [Related]
17. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Fröhlich E; Mack AF; Garbe C; Klessen C
Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
[TBL] [Abstract][Full Text] [Related]
18. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
19. Nevomelanocytic atypia detection by in vivo reflectance confocal microscopy.
Vaišnorienė I; Rotomskis R; Kulvietis V; Eidukevičius R; Zalgevičienė V; Laurinavičienė A; Venius J; Didžiapetrienė J
Medicina (Kaunas); 2014; 50(4):209-15. PubMed ID: 25458957
[TBL] [Abstract][Full Text] [Related]
20. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
